These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 11395137)

  • 1. Detection of viral superantigen-class II MHC interactions at the cell surface.
    Reilly M; Mix D; Winslow GM
    Mol Immunol; 2000 Nov; 37(16):987-93. PubMed ID: 11395137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intercellular transfer of a soluble viral superantigen.
    Reilly M; Mix D; Reilly AA; Ye XY; Winslow GM
    J Virol; 2000 Sep; 74(18):8262-7. PubMed ID: 10954523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Redundant proteolytic activation of a viral superantigen.
    Winslow GM; Cronin T; Mix D; Reilly M
    Mol Immunol; 1998 Oct; 35(14-15):897-903. PubMed ID: 9881685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteolytic processing activates a viral superantigen.
    Mix D; Winslow GM
    J Exp Med; 1996 Oct; 184(4):1549-54. PubMed ID: 8879228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A defective viral superantigen-presenting phenotype in HLA-DR transfectants is corrected by CIITA.
    Azar GA; Sékaly RP; Thibodeau J
    J Immunol; 2005 Jun; 174(12):7548-57. PubMed ID: 15944254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MMTV superantigens coerce an unconventional topology between the TCR and MHC class II.
    Fortin JS; Genève L; Gauthier C; Shoukry NH; Azar GA; Younes S; Yassine-Diab B; Sékaly RP; Fremont DH; Thibodeau J
    J Immunol; 2014 Feb; 192(4):1896-906. PubMed ID: 24453254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteolytic processing is required for viral superantigen activity.
    Park CG; Jung MY; Choi Y; Winslow GM
    J Exp Med; 1995 May; 181(5):1899-904. PubMed ID: 7722465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Processing and major histocompatibility complex binding of the MTV7 superantigen.
    Winslow GM; Marrack P; Kappler JW
    Immunity; 1994 Apr; 1(1):23-33. PubMed ID: 7889395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternative proteolytic processing of mouse mammary tumor virus superantigens.
    Denis F; Shoukry NH; Delcourt M; Thibodeau J; Labrecque N; McGrath H; Munzer JS; Seidah NG; Sékaly RP
    J Virol; 2000 Apr; 74(7):3067-73. PubMed ID: 10708421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diverse repertoire of the MHC class II-peptide complexes is required for presentation of viral superantigens.
    Golovkina T; Agafonova Y; Kazansky D; Chervonsky A
    J Immunol; 2001 Feb; 166(4):2244-50. PubMed ID: 11160278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The bacterial and mouse mammary tumor virus superantigens; two different families of proteins with the same functions.
    Marrack P; Winslow GM; Choi Y; Scherer M; Pullen A; White J; Kappler JW
    Immunol Rev; 1993 Feb; 131():79-92. PubMed ID: 8387458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transfer of endogenous retroviral superantigen from donor to recipient B cells following priming to induce peripheral T cell tolerance.
    Modlin CS; Todd GT; Cohen TD; Fairchild RL
    Cell Immunol; 1995 Sep; 164(2):217-26. PubMed ID: 7656330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paracrine transfer of mouse mammary tumor virus superantigen.
    Delcourt M; Thibodeau J; Denis F; Sekaly RP
    J Exp Med; 1997 Feb; 185(3):471-80. PubMed ID: 9053447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient presentation of endogenous superantigen by H-2Aq.
    Dyson PJ; Elliott J; Antoniou AN; Corley KT
    Eur J Immunol; 1998 Mar; 28(3):1034-9. PubMed ID: 9541599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of mouse mammary tumor virus superantigen with MHC class II during biosynthesis.
    Hsu PN; Wolf Bryant P; Sutkowski N; McLellan B; Ploegh HL; Huber BT
    J Immunol; 2001 Mar; 166(5):3309-14. PubMed ID: 11207286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct evidence for the role of COOH terminus of mouse mammary tumor virus superantigen in determining T cell receptor V beta specificity.
    Yazdanbakhsh K; Park CG; Winslow GM; Choi Y
    J Exp Med; 1993 Aug; 178(2):737-41. PubMed ID: 7688034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intercellular adhesion molecule-1 and leukocyte function-associated antigen-3 provide costimulation for superantigen-induced T lymphocyte proliferation in the absence of a specific presenting molecule.
    Lamphear JG; Stevens KR; Rich RR
    J Immunol; 1998 Jan; 160(2):615-23. PubMed ID: 9551895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bacterial and retroviral superantigens share a common binding region on class II MHC antigens.
    Torres BA; Griggs ND; Johnson HM
    Nature; 1993 Jul; 364(6433):152-4. PubMed ID: 8391645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transposon-mediated random insertions and site-directed mutagenesis prevent the trafficking of a mouse mammary tumor virus superantigen.
    McMahon CW; Traxler B; Grigg ME; Pullen AM
    Virology; 1998 Apr; 243(2):354-65. PubMed ID: 9568034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regions of mouse mammary tumor virus superantigen involved in interaction with the major histocompatibility complex class II I-A molecule.
    Wirth S; Vessaz A; Krummenacher C; Baribaud F; Acha-Orbea H; Diggelmann H
    J Virol; 2002 Nov; 76(21):11172-5. PubMed ID: 12368363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.